Target overview
Synonyms
FR alpha|FRα|FOLR1|Folate receptor alpha
Emerging Competitive
FRα / FOLR1 / Folate receptor alpha
FRα / FOLR1 / Folate receptor alpha is flagged as emerging competitive based on 8 active trials across 10 sponsors and 0 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 16
Active trials: 8
Recruiting trials: 5
Known assets: 0
Sponsor activity
Competitive footprint
Unique sponsors: 10
Top sponsors: AbbVie | Sutro Biopharma, . | Bristol-Myers Squibb
Tumor types: Fallopian Tube Cancer | Ovarian Cancer | Endometrial Cancer
Patent-density signal summary
Patent layer
Signal count: 0
Recent signals: 0
Top assignees: Unknown
Signal types: Unknown
Scores and labels
Deterministic summary
Clinical crowding: 4/5 (High)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 0/5 (Low)
Momentum: 3/5 (Rising)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.